MX348128B - 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol. - Google Patents

3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol.

Info

Publication number
MX348128B
MX348128B MX2014001600A MX2014001600A MX348128B MX 348128 B MX348128 B MX 348128B MX 2014001600 A MX2014001600 A MX 2014001600A MX 2014001600 A MX2014001600 A MX 2014001600A MX 348128 B MX348128 B MX 348128B
Authority
MX
Mexico
Prior art keywords
naphthyridinones
dihydro
pyrrole substituted
cyclopenta
antibacterial
Prior art date
Application number
MX2014001600A
Other languages
English (en)
Other versions
MX2014001600A (es
Inventor
Jerôme Emile Georges Guillemont
Anil Koul
David Francis Alain Lançois
Magali Madeleine Simone Motte
Wendy Mia Albert Balemans
Eric Pierre Alexandre Arnoult
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348128(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MX2014001600A publication Critical patent/MX2014001600A/es
Publication of MX348128B publication Critical patent/MX348128B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se relaciona con compuestos novedosos de fórmula (I) que inhiben la actividad de la enzima Fabl que, por lo tanto, son útiles para el tratamiento de infecciones bacterianas; se relaciona además con composiciones farmacéuticas que comprenden estos compuestos y con procesos químicos para preparar estos compuestos. (ver Fórmula).
MX2014001600A 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol. MX348128B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10
PCT/EP2012/065733 WO2013021054A1 (en) 2011-08-10 2012-08-10 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones

Publications (2)

Publication Number Publication Date
MX2014001600A MX2014001600A (es) 2014-04-25
MX348128B true MX348128B (es) 2017-05-26

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001600A MX348128B (es) 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol.

Country Status (24)

Country Link
US (7) US8906923B2 (es)
EP (1) EP2742045B1 (es)
JP (2) JP5921687B2 (es)
KR (1) KR101996862B1 (es)
CN (2) CN103874698B (es)
AR (1) AR087508A1 (es)
AU (1) AU2012293621B2 (es)
BR (1) BR112014003063B1 (es)
CA (1) CA2842518C (es)
CL (1) CL2014000289A1 (es)
DK (1) DK2742045T3 (es)
EA (1) EA201490438A1 (es)
ES (1) ES2721658T3 (es)
HU (1) HUE042978T2 (es)
IL (1) IL230549A (es)
JO (1) JO3611B1 (es)
MX (1) MX348128B (es)
PE (1) PE20141410A1 (es)
PH (1) PH12014500317A1 (es)
TR (1) TR201905537T4 (es)
TW (1) TWI568731B (es)
UA (1) UA111210C2 (es)
UY (1) UY34253A (es)
WO (1) WO2013021054A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
AU2012293619B2 (en) 2011-08-10 2017-05-04 Janssen Sciences Ireland Uc Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
WO2019177975A1 (en) 2018-03-12 2019-09-19 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
MA53668B1 (fr) 2018-09-19 2024-06-28 Novo Nordisk Health Care Ag Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
BR112021009106A2 (pt) 2018-11-12 2021-08-10 Debiopharm International S.A. compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
CA3212074A1 (en) * 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CO5251397A1 (es) 1999-10-08 2003-02-28 Smithkline Beecham Corp Inhibidores de fab i
HK1049656A1 (zh) 1999-10-08 2003-05-23 Smithkline Beecham Corporation Fab i抑制剂
US7049310B2 (en) 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
NZ599444A (en) 2009-11-18 2014-02-28 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｈｉｖの治療のための組成物および方法
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
AU2012293619B2 (en) 2011-08-10 2017-05-04 Janssen Sciences Ireland Uc Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
AU2012293618B2 (en) 2011-08-10 2017-04-20 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم

Also Published As

Publication number Publication date
PE20141410A1 (es) 2014-10-13
HK1223352A1 (zh) 2017-07-28
AR087508A1 (es) 2014-03-26
KR101996862B1 (ko) 2019-07-05
TW201313714A (zh) 2013-04-01
AU2012293621B2 (en) 2016-07-21
US9617262B2 (en) 2017-04-11
US9290493B2 (en) 2016-03-22
JP2016190843A (ja) 2016-11-10
US10155759B2 (en) 2018-12-18
US8906923B2 (en) 2014-12-09
KR20140072034A (ko) 2014-06-12
US20170174683A1 (en) 2017-06-22
UY34253A (es) 2013-02-28
HK1199243A1 (zh) 2015-06-26
AU2012293621A1 (en) 2014-02-13
UA111210C2 (uk) 2016-04-11
JP5921687B2 (ja) 2016-05-24
CA2842518C (en) 2019-07-23
CN105461684B (zh) 2018-09-25
CN103874698A (zh) 2014-06-18
TR201905537T4 (tr) 2019-05-21
US10526331B2 (en) 2020-01-07
CA2842518A1 (en) 2013-02-14
TWI568731B (zh) 2017-02-01
EP2742045B1 (en) 2019-01-23
MX2014001600A (es) 2014-04-25
IL230549A0 (en) 2014-03-31
BR112014003063B1 (pt) 2020-11-17
JO3611B1 (ar) 2020-08-27
DK2742045T3 (en) 2019-04-23
US9884864B2 (en) 2018-02-06
HUE042978T2 (hu) 2019-07-29
US10501463B2 (en) 2019-12-10
NZ620212A (en) 2015-10-30
CL2014000289A1 (es) 2014-07-11
US20140171451A1 (en) 2014-06-19
PH12014500317A1 (en) 2014-04-14
EP2742045A1 (en) 2014-06-18
WO2013021054A1 (en) 2013-02-14
JP2014531404A (ja) 2014-11-27
ES2721658T3 (es) 2019-08-02
BR112014003063A2 (pt) 2017-02-21
IL230549A (en) 2017-07-31
CN105461684A (zh) 2016-04-06
CN103874698B (zh) 2016-03-23
US20150080413A1 (en) 2015-03-19
US20190194194A1 (en) 2019-06-27
US20190084982A1 (en) 2019-03-21
EA201490438A1 (ru) 2014-06-30
US20160194324A1 (en) 2016-07-07
US20180105525A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
PH12014500317A1 (en) Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
NZ708928A (en) Mannose derivatives for treating bacterial infections
MX2014001599A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas.
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
MX2011005934A (es) Compuestos organicos.
WO2014007951A3 (en) Substituted tricyclic compounds as fgfr inhibitors
MX336189B (es) Compuesto de dihidroazol antiparasiticos y composiciones qe¡ue comprenden los mismos.
WO2013122888A3 (en) Methods of treating bacterial infections
PH12013500152A1 (en) New aminopyrazoloquinazolines
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX360856B (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX367309B (es) Nuevos compuestos antibacterianos.
MX2011008043A (es) Derivados de actagardina.
WO2012017434A3 (en) Guanine nucleotide derivatives for treating bacterial infections
MX363480B (es) Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
PH12013500219A1 (en) Compounds with antibacterial activity against clostridium
MX2013002398A (es) Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes.
MX2012004282A (es) Composiciones farmaceuticas.
PH12013501069A1 (en) Pharmaceutical compositions
TN2011000248A1 (en) Organic compounds
WO2012018662A3 (en) Fused-imidazoyl compounds useful as antimicrobial agents

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: JANSSEN SCIENCES IRELAND UC

FG Grant or registration